Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

ANACONDA (EGF VD)

Signature(s)

Amount
€ 10,000,000
Countries
Sector(s)
Spain : € 10,000,000
Industry : € 10,000,000
Signature date(s)
29/07/2021 : € 10,000,000
Link to source
Data sheet
ANACONDA (EGF VD)
Other links
Summary sheet
ANACONDA (EGF VD)
Related press
Spain: Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS)
Related story
A matter of life and death

Summary sheet

Release date
24 June 2021
Status
Reference
Approved | 05/07/2021
20210268
Project name
Promoter - financial intermediary
ANACONDA (EGF VD)
ANACONDA BIOMED SL
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 10 million
EUR 17 million
Location
Sector(s)
Description
Objectives

The project consists of financing the development of a new innovative catheter.

The proposed transaction will support research and development (R&D), manufacturing and product development costs for Anaconda, a company based in Spain based which develops a catheter system for mechanical thrombectomy.

Environmental aspects
Procurement

The Promoter's investments concern research, development and innovation activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during appraisal.

The Promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

Link to source
Summary sheet
ANACONDA (EGF VD)
Other links
Data sheet
ANACONDA (EGF VD)
Related press
Spain: Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS)

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

News & Stories

Link to source
Related press
Spain: Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS)
Related story
A matter of life and death
Other links
Data sheet
ANACONDA (EGF VD)
Summary sheet
ANACONDA (EGF VD)

Photogallery

Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS)
Anaconda (EGF VD)
©Anaconda Biomed

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

Related publications